



## FULL ANALYSIS

### I. SUBSTANTIVE ANALYSIS

#### A. DOES THE BILL:

- |                                      |                                         |                             |                                         |
|--------------------------------------|-----------------------------------------|-----------------------------|-----------------------------------------|
| 1. Reduce government?                | Yes <input checked="" type="checkbox"/> | No <input type="checkbox"/> | N/A <input type="checkbox"/>            |
| 2. Lower taxes?                      | Yes <input type="checkbox"/>            | No <input type="checkbox"/> | N/A <input checked="" type="checkbox"/> |
| 3. Expand individual freedom?        | Yes <input type="checkbox"/>            | No <input type="checkbox"/> | N/A <input checked="" type="checkbox"/> |
| 4. Increase personal responsibility? | Yes <input checked="" type="checkbox"/> | No <input type="checkbox"/> | N/A <input type="checkbox"/>            |
| 5. Empower families?                 | Yes <input checked="" type="checkbox"/> | No <input type="checkbox"/> | N/A <input type="checkbox"/>            |

For any principle that received a "no" above, please explain:

The bill expands government by creating a new program. On the other hand, impact on the government may be reduced if more individuals receive pharmaceutical assistance through private programs, thereby reducing the numbers who become eligible for state assistance.

#### B. EFFECT OF PROPOSED CHANGES:

The pharmaceutical industry has created pharmaceutical assistance programs (PAPs) that provide low income individuals with prescription drugs for free or at reduced prices. In 2001, more than 3.5 million patients received prescription medicines through PAPs, and PAPs provided almost 10 million prescriptions, with a wholesale value of about \$1.5 billion, to individuals nationwide.

Despite the success of PAPs, some seniors are unaware that they exist. Others know PAPs exist, but need help filling out the applications.

The bill establishes the Sunshine for Seniors Program, which will help seniors obtain prescription drugs from PAPs. Individuals who lack adequate pharmaceutical insurance coverage and are age 60 or older will be eligible for assistance.

The bill directs the Department of Elderly Affairs (DOEA), with assistance from the Agency for Health Care Administration, to implement the Sunshine for Seniors Program. To ensure Floridians know about the Sunshine for Seniors program, DOEA is required to promote the program statewide. DOEA will use its network of volunteers to help seniors obtain pharmaceutical assistance. The volunteers will determine if the seniors qualify for PAPs, and if they do, the volunteers will assist the seniors in filling out the necessary applications.

Currently, there are as many applications as there are PAPs. DOEA is required to develop a single application that can be used for all PAPs.

DOEA is authorized to use this program to build partnerships with communities to help seniors receive other needed charitable health services.

DOEA will report annually to the Legislature on the status of the Sunshine for Seniors Program.

#### C. SECTION DIRECTORY:

**Section 1.** Creates s. 430.83, F.S., which establishes the Sunshine for Seniors Program that assists low income seniors with obtaining prescription drugs from manufacturers' pharmaceutical assistance programs.

**Section 2.** Provides that this act shall take effect upon becoming a law.

## II. FISCAL ANALYSIS & ECONOMIC IMPACT STATEMENT

### A. FISCAL IMPACT ON STATE GOVERNMENT:

1. Revenues:

N/A

2. Expenditures: FY 2003-04

Recurring Expenditures

Other Personal Services	\$ 38,754
Expenses	\$ 27,906
Contracted Services	<u>\$160,000</u>
General Revenue Fund	\$226,660

### B. FISCAL IMPACT ON LOCAL GOVERNMENTS:

1. Revenues:

None

2. Expenditures:

None

### C. DIRECT ECONOMIC IMPACT ON PRIVATE SECTOR:

The Sunshine for Seniors Program will economically impact the pharmaceutical manufacturers since they will be making charitable contributions of their prescription drugs. However, at this time we have no estimates as to how much of an impact this will have on the pharmaceutical manufacturers.

### D. FISCAL COMMENTS:

None

## III. COMMENTS

### A. CONSTITUTIONAL ISSUES:

a. Applicability of Municipality/County Mandates Provision

This bill does not require municipalities or counties to spend money.

2. Other

None

### B. RULE-MAKING AUTHORITY:

None

C. DRAFTING ISSUES OR OTHER COMMENTS:

None

**IV. AMENDMENTS/COMMITTEE SUBSTITUTE CHANGES**

## FULL ANALYSIS

### I. SUBSTANTIVE ANALYSIS

#### A. DOES THE BILL:

- |                                      |                              |                             |                              |
|--------------------------------------|------------------------------|-----------------------------|------------------------------|
| 1. Reduce government?                | Yes <input type="checkbox"/> | No <input type="checkbox"/> | N/A <input type="checkbox"/> |
| 2. Lower taxes?                      | Yes <input type="checkbox"/> | No <input type="checkbox"/> | N/A <input type="checkbox"/> |
| 3. Expand individual freedom?        | Yes <input type="checkbox"/> | No <input type="checkbox"/> | N/A <input type="checkbox"/> |
| 4. Increase personal responsibility? | Yes <input type="checkbox"/> | No <input type="checkbox"/> | N/A <input type="checkbox"/> |
| 5. Empower families?                 | Yes <input type="checkbox"/> | No <input type="checkbox"/> | N/A <input type="checkbox"/> |

For any principle that received a "no" above, please explain:

#### B. EFFECT OF PROPOSED CHANGES:

#### C. SECTION DIRECTORY:

### II. FISCAL ANALYSIS & ECONOMIC IMPACT STATEMENT

#### E. FISCAL IMPACT ON STATE GOVERNMENT:

3. Revenues:

4. Expenditures:

#### F. FISCAL IMPACT ON LOCAL GOVERNMENTS:

3. Revenues:

4. Expenditures:

#### G. DIRECT ECONOMIC IMPACT ON PRIVATE SECTOR:

#### H. FISCAL COMMENTS:

### III. COMMENTS

#### D. CONSTITUTIONAL ISSUES:

1. Applicability of Municipality/County Mandates Provision

2. Other

#### E. RULE-MAKING AUTHORITY:

#### F. DRAFTING ISSUES OR OTHER COMMENTS:

### IV. AMENDMENTS/COMMITTEE SUBSTITUTE CHANGES